Help Get Patients to Their LDL-C and A1C Goals: Welchol® (colesevelam HCl) and the ADDvantage Program™

Published Online: Friday, June 1, 2012
This product bulletin was brought to you by Daiichi Sankyo, Inc.

This product bulletin describes the efficacy and safety of Welchol, a bile acid sequestrant. Welchol is the first and only add-on to a statin and metformin that is approved by the FDA as an adjunct to diet and exercise to lower both low-density lipoprotein cholesterol (LDL-C) and glycated hemoglobin (A1C) levels in adults with primary hyperlipidemia and type 2 diabetes mellitus. It also describes the ADDvantage Program, an innovative program to help keep patients on their LDL-C and A1C medications by enabling them to save money on multiple prescriptions and providing valuable resources and tools to help get them to their LDL-C and A1C goals.

To view the  Welchol® (colesevelam HCl) product information, please click here

To view the full product bulletin, please click here or the image below.



Related Articles
XIGDUO XR combines two anti-hyperglycemic agents with complementary mechanisms of action, dapagliflozin (trade name in the U.S. FARXIGA™), an inhibitor of sodium-glucose cotransporter 2 (SGLT2), and metformin hydrochloride (HCl) extended-release, a biguanide, in a once-daily oral tablet.
Women who develop gestational diabetes mellitus tend to have daughters who become obese later in childhood.
Draft guidance by the United States Preventive Services Task Force advocates screening patients with certain risk factors for impaired glucose tolerance to delay or prevent the onset of, and long-term damage due to, T2DM.
The rate of type 1 diabetes mellitus among non-Hispanic white youth increased significantly over an 8-year period.
Latest Issues
$auto_registration$